ONCR · Oncorus, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| R&D | $54.74M | $44.68M | $27.15M |
| SG&A | $21.79M | $20.14M | $10.00M |
| Total Operating Expenses | $76.54M | $64.82M | $37.15M |
| D&A | $3.63M | $1.95M | $1.37M |
| Operating Income | ($76.54M) | ($64.82M) | ($37.15M) |
| Interest Expense | - | - | - |
| Income Tax | $0 | $0 | $0 |
| Net Income | ($77.42M) | ($64.76M) | ($48.30M) |
| EPS - Basic | ($2.56) | - | - |
| EPS - Diluted | ($2.56) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $25.71M | $100.75M | $130.31M |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Accounts Payable | $5.69M | $13.01M | $1.25M |
| Current Assets | $64.62M | $129.11M | $133.39M |
| Total Assets | $145.59M | $201.59M | $182.26M |
| Current Liabilities | $37.21M | $20.97M | $5.98M |
| Long-term Debt | $0 | - | - |
| Total Liabilities | $85.06M | $71.56M | $47.60M |
| Stockholders' Equity | $60.52M | $130.02M | $134.66M |
| Retained Earnings | ($272.01M) | ($194.59M) | ($129.82M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | ($61.69M) | ($49.82M) | ($36.81M) |
| Investing Cash Flow | ($33.01M) | ($32.73M) | ($1.06M) |
| Financing Cash Flow | $19.65M | $53.56M | $125.76M |
| CapEx | $19.93M | $9.55M | $1.06M |
| Free Cash Flow | ($81.62M) | ($59.37M) | ($37.86M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | - | - | - |
| EBITDA margin | - | - | - |
| Net margin | - | - | - |
| Free cash flow margin | - | - | - |
| FCF / Net income | 1.05 | 0.92 | 0.78 |
| R&D / Revenue | - | - | - |
| SG&A / Revenue | - | - | - |
| Effective tax rate | - | - | - |
| Return on assets | -53.2% | -32.1% | -26.5% |
| Return on equity | -127.9% | -49.8% | -35.9% |
| Return on invested capital | -99.9% | - | - |
| Liquidity | |||
| Current ratio | 1.74 | 6.16 | 22.29 |
| Quick ratio | 1.74 | 6.16 | 22.29 |
| Cash ratio | 0.69 | 4.80 | 21.78 |
| Leverage | |||
| Debt / Equity | 0.00 | - | - |
| Debt / Assets | 0.00 | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | 2.41 | 1.55 | 1.35 |
| Liabilities / Assets | 0.58 | 0.36 | 0.26 |
| Efficiency | |||
| Asset turnover | - | - | - |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | - |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | -18.1% | -74.5% | - |
| Net income growth (YoY) | -19.5% | -34.1% | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | -37.5% | -56.8% | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | -53.5% | -3.4% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Oncorus against the 5 most active filers in the same SIC group.